search
Back to results

Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function. (L2012-12)

Primary Purpose

Hypercholesterolemia

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
LIMICOL
PLACEBO
Sponsored by
Lescuyer Laboratory
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Hypercholesterolemia focused on measuring Hypercholesterolemia, LDL cholesterol

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: BMI between 25 and 35 kg/m² Subject has a stable weight for at least three months before the start of the study. LDL ≥ 1.50 g/L 0.9 g/L ≤ triglycerides ≤ 4.00 g/L Subject able and willing to comply with the protocol and agreeing to give his informed consent in writing; Subject affiliated with a social security scheme Exclusion Criteria: Subject having a confirmed or suspected food allergy, notably to one of the components of the study product; Subject suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator Subject with glaucoma Subject with uretroprostatic disorder Subjet anxious (score >9 HAD scale) Subject with diabetes Subjet with treatment anticoagulant

Sites / Locations

  • Clermont Université, Université Blaise Pascal, EA 3533, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), BP 10448
  • CRNH-Auvergne
  • Service de médecine du sport et des explorations fonctionnelles, CHU G. Montpied
  • Clinique de cardiopneumologie de DURTOL

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

LIMICOL

PLACEBO

Arm Description

LIMICOL : red yeast rice (with monacolin K, 2 mg), artichoke leaf extract, policosanols, French maritime Pine bark extract, Garlic extract, vitamins E, B2 and B3. 1 tablet during the 3 principal meals for 12 weeks.

dicalcium phosphate, calcium citrate, vegetable magnesium stearate, microcrystalline cellulose, Maltodextrin, Tricalcium phosphate, Beet powder, Yellow coloring shellac, Brown coloring shellac. 1 tablet during the 3 principal meals for 12 weeks.

Outcomes

Primary Outcome Measures

LDL-cholesterol levels (g/l) at the end of study
Effect of LIMICOL supplementation showed by ANCOVA analysis of LDL cholesterol (g/l), with baseline LDL as covariable

Secondary Outcome Measures

Muscle function on tissue biopsy
Mitochondrial respiration of muscle histology. Expressed as pmol/s/ml.
Total cholesterol
Total cholesterol. Expressed as g/l, variation (g/l and %) compared to baseline.
HDL-cholesterol
HDL. Expressed as g/l, variation (g/l and %) compared to baseline.
Triglycerides
Triglycerides. Expressed as g/l, variation (g/l and %) compared to baseline.
LDLox
oxydized LDL. Expressed as pg/ml, variation (pg/l and %) compared to baseline.
CoQ10
circulating coenzyme Q10. Expressed as pg/ml. variation (pg/l and %) compared to baseline.
ApoA1
Circulating ApoLipoprotein A1. Expressed as g/ml. variation (g/l and %) compared to baseline.
ApoB
Circulating ApoLipoprotein B. Expressed as g/ml. variation (g/l and %) compared to baseline.
Glycemia
Glycemia. Expressed as mmol/l. variation (mmol/l and %) compared to baseline.
Insulinemia
Insulinemia. Expressed as mUI/l. variation (mUI/l and %) compared to baseline.
Myoglobin
Myoglobin. Expressed as µgI/l. variation (µg/l and %) compared to baseline.
CK
Creatin kinase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
LD
Lactate Dehydrogenase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
AST
Aspartate transaminase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
ALT
Alanine transaminase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
ALP
Alkaline phosphatase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
GGT
Gamma-glutamyltransferase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Bilirubin
Bilirubin. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
Albumin
Albumin. Expressed as g/l. variation (g/l and %) compared to baseline.
Total Protein
Total Protein. Expressed as g/l. variation (g/l and %) compared to baseline.
usCRP
ultrasensible C-reactiv protein. Expressed as mg/l. variation (mg/l and %) compared to baseline.
Creatinin
Creatinin. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
Urea
Urea. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
VO2 MAX
VO2MAX. Expressed as ml/min/kg. variation (ml/min/kg and %) compared to baseline.
Max Strength
Max grip strength. Expressed as N. variation (N and %) compared to baseline.
Weight
Body Weight. Expressed as Kg. variation (Kg and %) compared to baseline.
Fat mass
Fat Mass measured by DEXA. Expressed as % body mass. variation (%) compared to baseline.

Full Information

First Posted
September 8, 2014
Last Updated
February 28, 2023
Sponsor
Lescuyer Laboratory
Collaborators
Hopital Gabriel Montpied, CRNH Auvergne, Clinique Médicale Cardio-Pneumologie de Durtol, Université d'Auvergne
search

1. Study Identification

Unique Protocol Identification Number
NCT05750602
Brief Title
Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.
Acronym
L2012-12
Official Title
Effect of the Food Supplement LIMICOL on LDL Cholesterol and Muscle Function in Subjects Who Undergo a Program of Physical Training (Double-blind, Randomized, Placebo-controlled Study).
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Completed
Study Start Date
November 2013 (Actual)
Primary Completion Date
July 2017 (Actual)
Study Completion Date
September 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lescuyer Laboratory
Collaborators
Hopital Gabriel Montpied, CRNH Auvergne, Clinique Médicale Cardio-Pneumologie de Durtol, Université d'Auvergne

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Cardiovascular disease (CVD), foremost among which ischemic heart disease and stroke, are the leading cause of mortality and morbidity in France. These diseases are multifactorial origin and even if it is not possible to act on risk markers such as age, sex, or heredity, risk factors like high cholesterol, smoking , hypertension, obesity, diabetes and physical inactivity, are the main target of prevention strategies. Dydlipidemias have a role in the formation of CVD in participating in the genesis of atherosclerosis. The cholesterol and LDL-cholesterol in particular is subject to oxidation process in plasma. The molecules of oxidized LDL-cholesterol, small and dense, easily penetrate the arterial endothelial wall and are greeted by macrophages. Following a succession of different processes including inflammation, atherosclerotic plaque is formed. The result is either an arteriopathy when the arterial lumen narrowing, or atherothrombosis in the event of plaque rupture. Given this pathophysiology, reduce blood lipids, including LDL-cholesterol and reducing oxidation and inflammation are interesting strategies in the context of cardiovascular prevention. Several scientific study showed that nutritional supplementation with some plant extracts such as artichokes, garlic, red yeast rice, or the sugar cane policosanol helps to reduce several cardiovascular risk factors including regulate concentrations of circulating lipids. In this study, we hypothesize that the food supplement LIMICOL contributes to reducing LDL cholesterol in the context of care for patients (dietary measures and physical activity)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia
Keywords
Hypercholesterolemia, LDL cholesterol

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LIMICOL
Arm Type
Experimental
Arm Description
LIMICOL : red yeast rice (with monacolin K, 2 mg), artichoke leaf extract, policosanols, French maritime Pine bark extract, Garlic extract, vitamins E, B2 and B3. 1 tablet during the 3 principal meals for 12 weeks.
Arm Title
PLACEBO
Arm Type
Placebo Comparator
Arm Description
dicalcium phosphate, calcium citrate, vegetable magnesium stearate, microcrystalline cellulose, Maltodextrin, Tricalcium phosphate, Beet powder, Yellow coloring shellac, Brown coloring shellac. 1 tablet during the 3 principal meals for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
LIMICOL
Intervention Description
Suplementation with LIMICOL, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
PLACEBO
Intervention Description
Suplementation with PLACEBO, 3 tablets per day, together with supervised physical activity (3 times per week) for 12 weeks.
Primary Outcome Measure Information:
Title
LDL-cholesterol levels (g/l) at the end of study
Description
Effect of LIMICOL supplementation showed by ANCOVA analysis of LDL cholesterol (g/l), with baseline LDL as covariable
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
Muscle function on tissue biopsy
Description
Mitochondrial respiration of muscle histology. Expressed as pmol/s/ml.
Time Frame
Week 0; Week 12
Title
Total cholesterol
Description
Total cholesterol. Expressed as g/l, variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
HDL-cholesterol
Description
HDL. Expressed as g/l, variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
Triglycerides
Description
Triglycerides. Expressed as g/l, variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
LDLox
Description
oxydized LDL. Expressed as pg/ml, variation (pg/l and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
CoQ10
Description
circulating coenzyme Q10. Expressed as pg/ml. variation (pg/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
ApoA1
Description
Circulating ApoLipoprotein A1. Expressed as g/ml. variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
ApoB
Description
Circulating ApoLipoprotein B. Expressed as g/ml. variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Glycemia
Description
Glycemia. Expressed as mmol/l. variation (mmol/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Insulinemia
Description
Insulinemia. Expressed as mUI/l. variation (mUI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Myoglobin
Description
Myoglobin. Expressed as µgI/l. variation (µg/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
CK
Description
Creatin kinase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
LD
Description
Lactate Dehydrogenase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
AST
Description
Aspartate transaminase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
ALT
Description
Alanine transaminase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
ALP
Description
Alkaline phosphatase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
GGT
Description
Gamma-glutamyltransferase. Expressed as UI/l. variation (UI/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Bilirubin
Description
Bilirubin. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Albumin
Description
Albumin. Expressed as g/l. variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Total Protein
Description
Total Protein. Expressed as g/l. variation (g/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
usCRP
Description
ultrasensible C-reactiv protein. Expressed as mg/l. variation (mg/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Creatinin
Description
Creatinin. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
Urea
Description
Urea. Expressed as µmol/l. variation (µmol/l and %) compared to baseline.
Time Frame
Week 0; Week 12
Title
VO2 MAX
Description
VO2MAX. Expressed as ml/min/kg. variation (ml/min/kg and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
Max Strength
Description
Max grip strength. Expressed as N. variation (N and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
Weight
Description
Body Weight. Expressed as Kg. variation (Kg and %) compared to baseline.
Time Frame
Week 0; Week 6; Week 12
Title
Fat mass
Description
Fat Mass measured by DEXA. Expressed as % body mass. variation (%) compared to baseline.
Time Frame
Week 0; Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI between 25 and 35 kg/m² Subject has a stable weight for at least three months before the start of the study. LDL ≥ 1.50 g/L 0.9 g/L ≤ triglycerides ≤ 4.00 g/L Subject able and willing to comply with the protocol and agreeing to give his informed consent in writing; Subject affiliated with a social security scheme Exclusion Criteria: Subject having a confirmed or suspected food allergy, notably to one of the components of the study product; Subject suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator Subject with glaucoma Subject with uretroprostatic disorder Subjet anxious (score >9 HAD scale) Subject with diabetes Subjet with treatment anticoagulant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martine Duclos, Pr
Organizational Affiliation
CHU G. Montpied
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clermont Université, Université Blaise Pascal, EA 3533, Laboratoire des Adaptations Métaboliques à l'Exercice en Conditions Physiologiques et Pathologiques (AME2P), BP 10448
City
Clermont-ferrand
ZIP/Postal Code
F-63000
Country
France
Facility Name
CRNH-Auvergne
City
Clermont-Ferrand
ZIP/Postal Code
F-63001
Country
France
Facility Name
Service de médecine du sport et des explorations fonctionnelles, CHU G. Montpied
City
Clermont-Ferrand
ZIP/Postal Code
F-63003
Country
France
Facility Name
Clinique de cardiopneumologie de DURTOL
City
Durtol
ZIP/Postal Code
F-63830
Country
France

12. IPD Sharing Statement

Learn more about this trial

Combined Effect of LIMICOL and Physical Activity on LDL Cholesterol and Muscle Function.

We'll reach out to this number within 24 hrs